How to win: Supply of HLA Sequencing Systems

About this contract

NHS Blood & Transplant (NHSBT) Histocompatibility & Immunogenetics function intends to undertake a Procurement Act 2023 tender exercise for the supply of HLA sequencing systems. Histocompatibility & Immunogenetics (H&I) is a strategic business function of NHSBT, providing testing and support in transplantation, specialised transfusion including the supply of selected blood products, immunogenetics, platelet and granulocyte immunology. Services are supplied through a national network of six laboratories across England. Building on our strengths as a national provider, NHSBT’s strategic aim is for its diagnostic services to become the preferred provider and supplier of choice for these services in the NHS in England. We would like to work with future suppliers to realise this ambition and to perform HLA typing in an efficient, timely and cost-effective manner to meet the demands and expectations of our customers and the patients we serve. Prior to commencing a formal procurement process and to help inform our strategy, NHSBT is seeking to engage with suppliers of commercially available HLA sequencing systems. Our current contract ends in August 2028 and NHSBT would like to improve ou

How to win contracts like this

• ✓Answer against the marking scheme, not the question text — NHS Blood and Transplant scores each response, so map your evidence to the published criteria and weightings.
• ✓At £11,200,000, expect quality and social value to carry a large share of the score — price alone rarely wins goods work.
• ✓Show recent, comparable delivery: name similar goods contracts you've delivered for public bodies, with measurable outcomes.
• ✓Start early: deadlines are tight and a strong bid takes iteration.

BidWriter drafts your responses from your company profile, scores them against the marking scheme, and tracks your whole pipeline. Free to start — no card needed.

Related resources